Cardiology 2013

Papaioannou, Theodore G

eng

Historical Article

Portraits

England

2013/07/11 06:00

Eur Heart J. 2013 May;34(20):1463-4.

URL: http://www.ncbi.nlm.nih.gov/pubmed/23841146

Author Address: Athens University Medical School. mkaramanou@uoa.gr

 

 

Reference Type:  Journal Article

Record Number: 670Author: Kelly, A., Kennedy, A., John, B. M., Duane, B., Lemanowicz, J. and Little, J.

Year: 2013

Title: A comparison of heart rate changes associated with levalbuterol and racemic albuterol in pediatric cardiology patients

Journal: Ann Pharmacother

Volume: 47

Issue: 5

Pages: 644-50

Date: May

Short Title: A comparison of heart rate changes associated with levalbuterol and racemic albuterol in pediatric cardiology patients

Alternate Journal: The Annals of pharmacotherapy

ISSN: 1542-6270 (Electronic)

1060-0280 (Linking)

DOI: 10.1345/aph.1S003

Accession Number: 23613097

Keywords: Adolescent

Albuterol/*adverse effects/chemistry/therapeutic use

Bronchoconstriction/drug effects

Bronchodilator Agents/*adverse effects/therapeutic use

Cardiovascular Diseases/*physiopathology

Child

Child, Preschool

Dose-Response Relationship, Drug

Female

Heart Rate/*drug effects

Hospitals, Pediatric

Humans

Infant

Male

Retrospective Studies

Abstract: BACKGROUND: To our knowledge, no data exist regarding the effect of levalbuterol and racemic albuterol on heart rate in pediatric cardiology patients. OBJECTIVE: To compare heart rate change in pediatric cardiology patients receiving levalbuterol and/or racemic albuterol. The secondary objective was to identify characteristics associated with heart rate changes observed with these drugs. METHODS: A review of electronic medical records at a pediatric academic hospital was conducted to determine the equivalence of heart rate change in patients receiving levalbuterol or racemic albuterol. Patients receiving at least 3 doses of levalbuterol and/or racemic albuterol during the study period were included if they were younger than 18 years and had a diagnosis of congenital heart disease (CHD), cardiomyopathy, or supraventricular tachycardia. Patients were excluded if they received a beta-blocker or continuous racemic albuterol or did not have documented pre- and postdose heart rates. RESULTS: One hundred ninety-two patients were included. One hundred forty-two received racemic albuterol, 40 received levalbuterol, and 10 received both racemic albuterol and levalbuterol. The mean increase in heart rate for patients receiving racemic albuterol and levalbuterol was 6.8 beats/min and 6.2 beats/min, respectively (p = 0.01). In patients with CHD, the racemic albuterol group experienced a mean heart rate increase of 6.6 beats/min compared to 6.3 beats/min in the levalbuterol group (p = 0.01). Equivalence was also determined in patients without surgical intervention and patients receiving concomitant cardiac and respiratory medications. Equivalence was not established in other analyzed subgroups secondary to insufficient sample sizes. CONCLUSIONS: Racemic albuterol and levalbuterol were associated with increased heart rate in pediatric cardiology patients. This increase was found to be equivalent.

Pages: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208